About: Evaluation of a novel real-time RT-PCR using TOCE technology compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of a novel real-time RT-PCR using TOCE technology compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Evaluation of a novel real-time RT-PCR using TOCE technology compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses
Creator	Cho, Yunjung Chulten, Bayarjavkhlan Cho, Chi Kim, Young Lee, Chang Lim, Chae Nam, Myung Yoon, Soo
topic	covid:fb8f2f72f6a73f6bc8e3c3109b68edb71a72f75b#this
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Various kinds of commercial molecular systems have been developed for fast and more accurate detection of respiratory viruses. Anyplex™ II RV16 [RV16] was designed for simultaneous detection of 16 respiratory viruses using multiplex PCR coupled with TOCE™ technology. OBJECTIVES: To compare the performance of RV16 with those of culture and Seeplex(®) RV15 ACE [RV15] by determining their sensitivity and specificity. STUDY DESIGN: Seven hundred and thirty respiratory samples were tested by modified shell vial culture method, RV16, and RV15. For molecular tests, automated nucleic acid extraction and liquid handling system using MICROLAB Nimbus IVD (Hamilton, USA) was adopted to maximize the workflow and accuracy. Performance of each assay was determined against a composite reference standard. RESULTS: Two hundred and one samples (28%) out of 730 samples were positive by culture, while additional 281 (39%) were positive by RV16 or RV15. Sensitivities of RV16, RV15, and culture for virus tested were as follows: 100/93/63% for influenza A, 90/80/69% for influenza B, 98/94/63% for RSV, 98/52/23% for adenovirus, and 100/75/46% for PIV. For viruses not covered by culture, sensitivities of RV16 and RV15 were as follows: 99/81% for rhinovirus, 92/100% for coronavirus OC43, 100/56% for coronavirus 229E/NL63, 92/88% for metapneumovirus, 100/62% for bocavirus, and 91/91% for enterovirus. Overall, the specificities of culture, RV16, and RV15 (Seegene) were 100/99.9/99.9%. CONCLUSIONS: RV16 assay was superior to culture method and RV15 and will be a promising tool for patient management and public health epidemiology.
has issue date	2013-06-03(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2013.04.014
bibo:pmid	23743345
has license	no-cc
sha1sum (hex)	fb8f2f72f6a73f6bc8e3c3109b68edb71a72f75b
schema:url	https://doi.org/10.1016/j.jcv.2013.04.014
resource representing a document's title	Evaluation of a novel real-time RT-PCR using TOCE technology compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses
has PubMed Central identifier	PMC7108272
has PubMed identifier	23743345
schema:publication	J Clin Virol
resource representing a document's body	covid:fb8f2f72f6a73f6bc8e3c3109b68edb71a72f75b#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/fb8f2f72f6a73f6bc8e3c3109b68edb71a72f75b
is schema:about of	named entity 'TECHNOLOGY' named entity 'Hamilton' named entity 'culture' named entity 'OC43' named entity 'maximize' named entity 'respiratory' named entity 'systems' named entity 'virus' named entity 'developed' named entity 'fast' named entity 'RT-PCR' named entity 'OVERALL' named entity 'CORONAVIRUS OC43' named entity 'DETERMINED' named entity 'WORKFLOW' named entity 'BOCAVIRUS' covid:arg/fb8f2f72f6a73f6bc8e3c3109b68edb71a72f75b named entity 'SPECIFICITIES' named entity 'ADOPTED' named entity '100%' named entity 'SUPERIOR' named entity 'FOLLOWS' named entity 'PATIENT MANAGEMENT' named entity 'ACCURACY' named entity 'TWO HUNDRED' named entity 'IVD' named entity 'ADDITIONAL' named entity 'COMMERCIAL' named entity 'TECHNOLOGY' named entity 'RESPIRATORY SAMPLES' named entity 'REFERENCE STANDARD' named entity 'CULTURE' named entity 'COMPOSITE' named entity 'STUDY DESIGN' named entity 'COUPLED' named entity 'PERFORMANCE' named entity 'KINDS' named entity 'REAL-TIME RT-PCR' named entity 'RESPIRATORY VIRUSES' named entity 'EVALUATION' named entity 'DETECTION' named entity 'USING' named entity 'LIQUID HANDLING SYSTEM' named entity 'MOLECULAR' named entity 'USA' named entity 'MULTIPLEX PCR' named entity 'ACCURATE' named entity 'RESPIRATORY VIRUSES' named entity 'FAST' named entity 'CULTURE' named entity 'NIMBUS' named entity 'BACKGROUND' named entity 'RESULTS' named entity 'ENTEROVIRUS' named entity 'SEVEN' named entity 'VIRUS' named entity 'VARIOUS' named entity 'NUCLEIC ACID EXTRACTION' named entity 'ASSAY' named entity 'ADENOVIRUS' named entity 'RHINOVIRUS' named entity 'INFLUENZA B' named entity 'COVERED BY' named entity 'MOLECULAR SYSTEMS' named entity 'CORONAVIRUS 229E' named entity 'CONCLUSIONS' named entity 'PIV' named entity 'AUTOMATED' named entity 'VIRUSES' named entity 'METAPNEUMOVIRUS' named entity 'DETECTION' named entity 'FOR PATIENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software